Klotho Therapeutics, Inc. (KTI), a San Diego, CA-based biotechnology company focused on commercializing its patent pending version of the protein/hormone Klotho, held the first closing of a $10m Series A financing.
The round was led by Thynk Capital.
The company intends to use the funds to advance Klotho development for kidney disease, for manufacturing scale-up, first in-human studies and Investigational New Drug (IND) application with the FDA.
Led by Jim Plante, founder and CEO, Klotho Therapeutics develops a patent-pending Klotho protein that has the potential to delay diseases of aging and help people live well longer. Naturally occurring in humans and animals, Klotho positively influences longevity, cognition and kidney function as well as slowing progression of diabetes and cancer.
This round builds upon the $100+ million invested in Klotho-related academic research that demonstrated the proteine/hormone’s positive impact on kidney function, cognition, fibrosis, cancer and longevity. Klotho is found naturally in humans and animals.
KTI, which operates virtually, has worldwide patents pending on versions of modified and recombinant Klotho that can be readily manufactured using standard cell culture technology.